Mean Six-Minute Walk Distance Improved in ERT-Naive Patients (+42 Meters at 6 Months, +75 Meters at 9 Months) and ERT-Switch Patients (+35 Meters at 6 Months, +37 Meters at 9 Months) Persistent & Durable Reductions in Key Disease Biomarkers Pulmonary Function Generally Improved or Remained
CRANBURY, N.J. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New
Study Did Not Meet Primary Endpoints Conference Call and Webcast Today at 8:30am ET CRANBURY, N.J. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics , Inc. (Nasdaq:FOLD) reported that top-line data from the randomized, double-blind, placebo-controlled Phase 3 clinical study (ESSENCE, SD-005)
CRANBURY, N.J. , Aug. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that 6 posters highlighting its Fabry program will be included in the 13 th International Congress of Inborn Errors of Metabolism to be held September 5-8, 2017 in Rio de Janeiro, Brazil .
First Amicus Medicine and First Oral Precision Medicine for Fabry Disease in Australia Broad Label for Fabry Patients with an Amenable Genetic Mutation CRANBURY, N.J. , Aug. 15, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Australian Therapeutic Goods Administration
179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 - On Target to Reach 300 Patients by Year-End 2017 Migalastat NDA Submission Targeted for 4Q17 Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17 CRANBURY, N.J. , Aug.
CRANBURY, N.J. , July 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on August 7, 2017 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2017 . The call will be hosted by John F.